NASDAQ, TSX: NVCN
VANCOUVER, July 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the
"Company") (NASDAQ, TSX: NVCN) announced today that, in connection with its new final short form base shelf prospectus (the "Base
Shelf Prospectus") filed with securities regulatory authorities in the provinces of British
Columbia, Alberta, Saskatchewan, Manitoba and Ontario (the "Provinces") and its corresponding shelf
registration statement on Form F-10 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC")
under the U.S./Canada Multijurisdictional Disclosure System, which were filed to replace its prior expiring base shelf prospectus
and related registration statement, the Company has filed a prospectus supplement (the "Prospectus Supplement") with the
securities regulatory authorities in the Provinces and with the SEC covering the issuance, from time to time, of units, warrants
and common shares of the Company underlying the outstanding warrants previously issued pursuant to the Company's underwritten
public offering of 6,609,588 Series A units of the Company and 19,066,780 Series B units of the Company at a price of
$1.46 per unit, which closed on November 17, 2017. This
"administrative" filing effectively moves the registration of these underlying units, warrants and common shares from the
Company's prior registration statement, which expired on July 9, 2018, to the new Registration
Statement. It does not involve a new financing.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of
these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction.
A copy of the Registration Statement, including the related prospectus, or the Prospectus Supplement may be obtained by
submitting a request to Chris Clark, Chief Financial Officer, at Neovasc's address at 5138-13562
Maycrest Way, Richmond, British Columbia, Canada, V6V 2J7. Copies of the Base Shelf Prospectus
and Prospectus Supplement are available on SEDAR at www.sedar.com. Copies of the Registration Statement can be found on the SEC website at www.sec.gov.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Neovasc ReducerTM (the "Reducer"), for the treatment of
refractory angina, which is not currently commercially available in the United States and has
been commercially available in Europe since 2015, and the TiaraTM (the "Tiara"), for
the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe.
View original content:http://www.prnewswire.com/news-releases/neovasc-announces-filing-of-administrative-prospectus-supplement-relating-to-expiry-of-prior-shelf-prospectus--registration-statement-300680996.html
SOURCE Neovasc Inc.
View original content: http://www.newswire.ca/en/releases/archive/July2018/16/c2404.html